Kenneth D James

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 4 EPO patents. Top assignees: Biocon Limited, Nobex Corporation. Active years: 2003-2015.

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 80.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 109(Granted Patents)

Company Filing History:

Years Active: 2003-2015

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9102758 - Insulin-oligomer conjugates, formulations and uses thereof (2015-08-11),

2. 9101596 - Cation complexes of insulin compound conjugates, formulations and uses thereof (2015-08-11),

3. 8759290 - Oral glucagon-like peptide conjugates for metabolic diseases (2014-06-24),

4. 8563685 - Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof (2013-10-22),

5. 7875700 - Cation complexes of insulin compound conjugates, formulation and uses thereof (2011-01-25),

6. 7872095 - Insulin-oligomer conjugates, formulations and uses thereof (2011-01-18),

7. 7662773 - Natriuretic compounds, conjugates, and uses thereof (2010-02-16),

8. 7648962 - Natriuretic compounds, conjugates, and uses thereof (2010-01-19),

9. 7605123 - Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof (2009-10-20),

10. 6593492 - Resolution of intermediates in the synthesis of substantially pure bicalutamide (2003-07-15),

Title: The Innovative Mind of Kenneth D James

Introduction

Kenneth D James, an inventive force hailing from Mebane, North Carolina, has made significant strides in the field of biotechnology with a focus on insulin compounds. With a portfolio of ten patents, his contributions are largely centered around unique formulations and methodologies that advance the efficacy of insulin treatments.

Latest Patents

Among his most recent patents are the "Cation complexes of insulin compound conjugates, formulations and uses thereof," which explores a novel insulin compound interfaced with a modifying moiety featuring a precise formula. Another noteworthy invention is the "Insulin-oligomer conjugates, formulations and uses thereof," wherein an insulin conjugate is created by linking insulin with a modifying moiety based on a sophisticated framework of linking groups and a carbon chain imbued with one or more alkylene glycol moieties. These patents embody his exceptional creativity and scientific insight.

Career Highlights

Kenneth has had a rewarding career, collaborating with prominent companies such as Biocon Limited and Nobex Corporation. His work at these esteemed organizations has allowed him to refine his expertise in bioconjugation, paving the way for groundbreaking innovations in the treatment of diabetes and other health conditions.

Collaborations

Throughout his career, Kenneth has worked alongside notable colleagues, including Nnochiri Ekwuribe and Navdeep Balkrishna Malkar. These collaborations have undoubtedly fueled mutual growth and led to the development of innovative solutions within the biopharmaceutical arena.

Conclusion

Kenneth D James exemplifies the spirit of innovation through his impressive patent portfolio and his commitment to advancing medical technology. His ongoing contributions to the field of insulin formulations offer not only promise for enhanced therapies but also demonstrate the power of collaboration and creativity in science. As he continues to push the boundaries of research and development, Kenneth remains a pivotal figure in the landscape of biotechnological innovation.